Dr. Rosenberg on Enfortumab Vedotin/Pembrolizumab in Urothelial Carcinoma

Jonathan E. Rosenberg, MD
Published: Tuesday, Mar 31, 2020



Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the updated results of the phase Ib/II EV-103 trial (NCT03288545) with enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) in patients with locally advanced or metastatic urothelial carcinoma.

Data presented at the 2019 ESMO Congress showed a 71% objective response rate (ORR) with the combination in patients who were ineligible for cisplatin-based chemotherapy. According to updated findings presented at the 2020 Genitourinary Cancers Symposium, the ORR increased to 73%, says Rosenberg. Additionally, the complete response rate was 15.6%. Notably, responses were observed irrespective of PD-L1 expression.

Moreover, the median progression-free survival was 12.3 months, which compares favorably to historical rates with carboplatin, says Rosenberg. The median overall survival (OS) was not reached at the time of data cutoff, and the 1-year OS rate was 81.6%. These results are highly encouraging but should be taken within the context of the population size of the trial, says Rosenberg. Further analysis from the results of the expansion cohort are highly anticipated, he concludes.
SELECTED
LANGUAGE


Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the updated results of the phase Ib/II EV-103 trial (NCT03288545) with enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) in patients with locally advanced or metastatic urothelial carcinoma.

Data presented at the 2019 ESMO Congress showed a 71% objective response rate (ORR) with the combination in patients who were ineligible for cisplatin-based chemotherapy. According to updated findings presented at the 2020 Genitourinary Cancers Symposium, the ORR increased to 73%, says Rosenberg. Additionally, the complete response rate was 15.6%. Notably, responses were observed irrespective of PD-L1 expression.

Moreover, the median progression-free survival was 12.3 months, which compares favorably to historical rates with carboplatin, says Rosenberg. The median overall survival (OS) was not reached at the time of data cutoff, and the 1-year OS rate was 81.6%. These results are highly encouraging but should be taken within the context of the population size of the trial, says Rosenberg. Further analysis from the results of the expansion cohort are highly anticipated, he concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x